ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

EOLS vs MNPR // RETURN ON INVESTED CAPITAL (ROIC)

Evolus Inc. (NASDAQ) VS. Monopar Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: EOLS 3 — MNPR 2
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MNPR
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EOLS VS. MNPR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC EOLS MNPR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 66.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -17.40% -17.60 MNPR /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -9.20% -2.53% -6.67 MNPR /fcf-yield <GO>
Operating Margin -11.00% — — TIE /operating-margins <GO>
Net Profit Margin -17.40% — — TIE /net-margins <GO>
Revenue Growth (YoY) 11.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 EOLS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.1 33.4 +12.69 EOLS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $496.7M $482.7M $14.0M EOLS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR EOLS REV MNPR REV EOLS GROSS % MNPR GROSS % EOLS FCF MNPR FCF
FY 2025 $297.2M $0 66.3% — -$45.7M -$12.2M
FY 2024 $266.3M $0 68.5% — -$19.5M -$6.4M
FY 2023 $202.1M $0 — — -$34.0M -$7.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EOLS // BETA —
MNPR // BETA —